Difference between revisions of "Mitotane"
m (Stub sorting and placement of stub template(s)) |
m (1 revision) |
(No difference)
| |
Latest revision as of 10:23, 20 September 2010
| 400px | |
| Systematic (IUPAC) name | |
|---|---|
|
(RS)-1-chloro-2-[2,2-dichloro-1-(4-chlorophenyl)-ethyl]-benzene | |
| Clinical data | |
| [[Regulation of therapeutic goods |Template:Engvar data]] | |
| Pregnancy category |
|
| Routes of administration | Oral |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 40% |
| Protein binding | 6% |
| Biological half-life | 18 to 159 days |
| Identifiers | |
| CAS Number | 53-19-0 |
| ATC code | L01XX23 (WHO) |
| PubChem | CID 4211 |
| DrugBank | APRD00494 |
| Chemical data | |
| Formula | C14H10Cl4 |
| Molar mass | 320.04 g/mol[[Script error: No such module "String".]] |
| (verify) | |
Mitotane, or o,p'-DDD, is an antineoplastic medication used in the treatment of adrenocortical carcinoma.[1] It is an isomer of DDD and is a derivative of DDT.[2] Its main use is in those patients who have persistent disease despite surgical resection, those who are not surgical candidates, or those who have metastatic disease.
It has been produced by Bristol Myers Squibb SpA but it is marketed as an orphan drug due to the small number of patients in need of it. A 2007 study of 177 patients shows a significant increase in the recurrence-free interval after radical surgery followed by Mitotane when compared to surgery alone.[3]
Mitotane alters steroid peripheral metabolism, directly suppresses the adrenal cortex and alters cortisone metabolism leading to hypocortisolism. Side effects as reported by Schteinberg et al. include anorexia and nausea (88%), diarrhea (38%), vomiting (23%), decreased memory and ability to concentrate (50%), rash (23%), gynecomastia (50%), arthralgia (19%), and leukopenia (7%).[4]
Its trade name is Lysodren.
Veterinary use
Mitotane is also used to treat pituitary-dependent Cushing's syndrome in canines. The medication is used in the controlled destruction of adrenal tissue, leading to a decrease in cortisol production.[5]
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />External links
| 40px | This antineoplastic or immunomodulatory drug article is a stub. You can help ssf by expanding it. |
- ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
- ↑ Information from PubChem
- ↑ Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA, Rossetto R, Buci L, Sperone P, Grossrubatscher E, Reimondo G, Bollito E, Papotti M, Saeger W, Hahner S, Koschker AC, Arvat E, Ambrosi B, Loli P, Lombardi G, Mannelli M, Bruzzi P, Mantero F, Allolio B, Dogliotti L, Berruti A. "Adjuvant mitotane treatment for adrenocortical carcinoma". N Engl J Med. 2007 Jun 7;356(23):2372-80.
- ↑ Schteinberg DE, Motazedi A, NoonanRA, Thompson NW. "Treatment of Adrenal Carcinomas". Arch.Surg. (1982) 117:1142-9.
- ↑ Canine Cushing’s Syndrome: Diagnosis and Treatment
- Pages with script errors
- Pages with broken file links
- Drugs with non-standard legal status
- Infobox drug articles with non-default infobox title
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- 2Fix
- Orphan drugs
- Antineoplastic drugs
- Organochlorides
- Antineoplastic and immunomodulating drug stubs
- CS1 maint: Multiple names: authors list
-Mitotane_Enantiomers_Structural_Formulae.png){kind=link}
